BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26679966)

  • 1. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.
    Levin P; Zhou S; Durden E; Farr AM; Gill J; Wei W
    Clin Ther; 2016 Jan; 38(1):110-21. PubMed ID: 26681210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization.
    Aagren M; Luo W; Moës E
    J Med Econ; 2010 Mar; 13(1):16-22. PubMed ID: 19958212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Economic Outcomes of Patients with Type 2 Diabetes on Multiple Daily Injections of Basal-bolus Insulin (MDI) Therapy: A Retrospective Cohort Study.
    Brixner D; Ermakova A; Xiong Y; Sieradzan R; Sacks N; Cyr P; Taylor SD
    Clin Ther; 2019 Feb; 41(2):303-313.e1. PubMed ID: 30709610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with Basal-Bolus Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Effect on Clinical and Economic Outcomes: A Retrospective Claims Database Study.
    Edelman SV; Ermakova A; Xiong Y; Sieradzan R; Taylor SD
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1420-1431. PubMed ID: 31550190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
    J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Patterns and Glycemic Control in Older Adults with Type 2 Diabetes Mellitus Receiving Only Oral Antidiabetes Drugs in China.
    Zhang L; Ji L; Guo L; Lu J; Tian H; Zhu D; Xing X; Weng JP; Jia W
    Diabetes Technol Ther; 2015 Nov; 17(11):816-24. PubMed ID: 26448574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.
    Gu Y; Hou X; Zhang L; Pan J; Cai Q; Bao Y; Jia W
    Diabetes Technol Ther; 2012 Mar; 14(3):244-50. PubMed ID: 22047050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycosylated hemoglobin level and number of oral antidiabetic drugs predict whether or not glycemic target is achieved in insulin-requiring type 2 diabetes.
    Lin SD; Tsai ST; Tu ST; Su CC; Chen JF; Lu CH; Wang CH; Yu NC; Hsu SR; Hsieh MC
    Prim Care Diabetes; 2015 Apr; 9(2):135-41. PubMed ID: 25266893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and safety of initiation of once-daily insulin detemir in Chinese patients with type 2 diabetes previously treated with different quantities of oral anti-diabetic drugs: subgroup analysis of the Chinese SOLVE™ Study].
    Pan C; Ji L; Lu J; Yang W; Zhou Z;
    Zhonghua Nei Ke Za Zhi; 2015 Jul; 54(7):612-7. PubMed ID: 26359024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.